Can Direct-Acting Antiviral Treatment Change the Immunologic Risk Profile in Patients Infected with Hepatitis C Virus Who Are on the Cadaveric Waiting List?

Bayraktar A. , Akgul S. U. , Bakkaloglu H. , Temurhan S. , Cinar C. K. , Ciftci H. S. , et al.

TRANSPLANTATION PROCEEDINGS, cilt.52, ss.97-101, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier


Background. In patients with hepatitis C virus (HCV) infection, the activation of the immune system by the virus or viral proteins leads to the production of numerous auto-antibodies and clinical manifestations. The objectives of this study were to investigate the relationship between HCV and anti-HLA antibodies, as well as the effect of viremia on the antibody response and of direct-acting antivirals (DAAs) on anti-HLA antibody persistence in patients on the waiting list for a cadaveric kidney transplant.